大剂量人免疫球蛋白联合地塞米松治疗Guillian-Barre综合征的临床研究  

High-dose human immunoglobulin combined with Dexamethasone in treatment of Guillian-Barre syndrome

作　　者：邵艳敏[1] 武文娟[1] 张育德[1] SHAO Yan- rain;WU Weng - juan;ZHANG Yu - de(The First Affiliated Hospital of Henan University of science and Tec, hnology, Luoyang, Henan 471000, China)

机构地区：[1]河南科技大学第一附属医院神经内科,河南洛阳471000

出　　处：《医药论坛杂志》2018年第3期27-29,32,共4页Journal of Medical Forum

摘　　要：目的探讨大剂量人免疫球蛋白联合地塞米松治疗格林-巴利综合征(Guillian-Barre综合征)的临床疗效及安全性。方法从河南科技大学第一附属医院2013年2月—2017年4月就诊的Guillian-Barre综合征患者中选取126例作为研究对象,随机分为2组,63例给予常规甲基强的松龙治疗为常规组,63例给予大剂量人免疫球蛋白联合鞘内注射地塞米松治疗患者为研究组,对比两组患者治疗疗效及不良反应发生率的情况。结果治疗第2周、第3周、第4周、第5周研究组患者CSF中蛋白质含量及白细胞升高例数均显著低于常规组,差异有统计学意义(χ~2=4.202,χ~2=30.631,χ~2=36.000,χ~2=6.540,P<0.05);研究组患者神经功能缺损程度评分显著低于常规组,差异有统计学意义(t=7.154,P<0.05);研究组治疗总显效率90.5%显著高于常规组治疗总显效率74.6%,差异有统计学意义(χ~2=5.507,P<0.05)。结论 Guillian-Barre综合征患者给予大剂量人免疫球蛋白联合地塞米松治疗疗效显著,能有效改善患者神经功能缺损程度,且安全可靠。Objective To investigate the clinical efficacy and safety of high - dose human immunoglobulin combined with dexamethasone in the treatment of Guillian Barre syndrome. Methods Totally 126 patients with Guillian - Barre syndrome in our hospital from February 2013 to April 2017 were selected and randomly divided into two groups. 63 patients treated with dexamethasone were included into conventional group and 63 patients treated with high - dose human immu- noglobulin combined with dexamethasone were enrolled in study group. Then the curative effect and the incidence of ad- verse reactions in two groups were compared. Results The protein levels and the number of leukocytosis in the CSF in the study group were significantly lower than those in the conventional group at the second, third, fourth, and fifth weeks, and the difference was statistically significant（χ2 =4. 202, X2 =30. 631, X2 =36. 000, X2 =6. 540, P 〈0. 05） ; The neurological deficit score of the study group was significantly lower than that of the conventional group, the differenee was statistically significant （t = 7. 154, P 〈 0. 05） ; The total effective rate of the study group was 90. 5 %, signifi- cantly higher than 74.6% of the conventional group, the difference was statistically significant （ X2 = 5. 507, P 〈 0. 05 ）. Conclusion Patients with Guillian - Barre syndrome treated with large dose of Human immunoglobulin combined with dexamethasone have significant curative effect, and can effectively improve the degree of neurological impair- ment with high safety, which is more reliable.

关 键 词：免疫球蛋白 地塞米松 格林-巴利综合征 

分 类 号：R744.5[医药卫生—神经病学与精神病学]